Analysis of the synergistic effect of triptolide combined with gefitinib on <italic style="font-style: italic">EGFR</italic>-mutant NSCLC cells

ZHANG Yi; GUO Fen

doi:10.6039/j.issn.1001-0408.2023.18.09

您当前的位置：

首页 >

文章列表页 >

Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells

更新时间：2025-09-26

- Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells
- ZHONGGUO YAOFANG Vol. 34, Issue 18, Pages: 2219-2225(2023)
- 作者机构：
  
  1.咸宁市中心医院/湖北科技学院附属第一医院呼吸与危重症医学科，湖北咸宁　437100
  2.湖北科技学院临床医学院医学实验实训中心，湖北咸宁　437100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.18.09
  CLC： R965
- Received：02 March 2023，
  
  Revised：2023-08-03，
  
  Accepted：08 August 2023，
  
  Published：30 September 2023
- 稿件说明：
移动端阅览
张艺,郭芬.雷公藤甲素联合吉非替尼对EGFR突变NSCLC细胞的协同效应分析[J].中国药房,2023,34(18):2219-2225.

ZHANG Yi,GUO Fen.Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells[J].ZHONGGUO YAOFANG,2023,34(18):2219-2225.
张艺,郭芬.雷公藤甲素联合吉非替尼对EGFR突变NSCLC细胞的协同效应分析[J].中国药房,2023,34(18):2219-2225. DOI： 10.6039/j.issn.1001-0408.2023.18.09.

ZHANG Yi,GUO Fen.Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells[J].ZHONGGUO YAOFANG,2023,34(18):2219-2225. DOI： 10.6039/j.issn.1001-0408.2023.18.09.

摘要

目的

探讨雷公藤甲素（TPL）联合表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）吉非替尼对

EGFR

突变非小细胞肺癌（NSCLC）细胞的协同效应及潜在机制。

方法

体外培养人NSCLC细胞系H1975（

EGFR

T790M/L858R突变的耐药细胞系）和H1299（

EGFR

野生型的非耐药细胞系），采用MTT法检测细胞存活率并通过联合用药指数（CI）评价TPL和吉非替尼的联用效应。将H1975细胞分为空白组，低、高浓度TPL组（5、15 nmol/L），吉非替尼组（2 μmol/L），低浓度TPL+吉非替尼组、高浓度TPL+吉非替尼组（5 nmol/L TPL+2 μmol/L吉非替尼、15 nmol/L TPL+2 μmol/L吉非替尼），采用流式细胞术检测其凋亡及周期分布情况；利用分子对接技术预测TPL与EGFR的结合能力，并采用流式细胞术检测细胞中磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白（PI3K/Akt/mTOR）通路及自噬相关蛋白[微管相关蛋白1轻链3α（MAP1LC3A）、MAP1LC3B

]

的表达情况。

结果

TPL对H1975和H1299细胞的增殖均有一定的抑制作用，且有浓度、时间依赖趋势；5或15 nmol/L TPL联合吉非替尼作用48 h对H1975细胞的增殖均有协同抑制效应（CI＜1），而对H1299细胞则无协同作用（CI＞1）。与空白组比较，各药物组的细胞凋亡率和G

期细胞的比例均显著升高，S期、G

/M期（个别TPL组除外）细胞的比例均显著降低，且联用组效果更优（

＜0.05）。分子对接结果显示，TPL的羟基可与

EGFR

T790M/L858R突变编码产物的Thr854残基形成氢键。与空白组比较，各药物组细胞中通路相关蛋白的表达均显著下调，自噬相关蛋白的表达均显著上调，且联用组效果更优（

＜0.05）。

结论

TPL联合吉非替尼可协同抑制

EGFR

突变NSCLC细胞的增殖活性，其作用机制可能与下调PI3K/Akt/mTOR通路和诱导细胞自噬有关。

Abstract

OBJECTIVE

To investigate the synergistic effect of triptolide （TPL） combined with epidermal growth factor receptor tyrosine kinas

e inhibitor （EGFR-TKI） gefitinib on

EGFR

-mutated non-small cell lung cancer （NSCLC） cells and its potential mechanism.

METHODS

Human NSCLC cell lines H1975 （

EGFR

T790M/L858R mutated drug-resistant cell lines） and H1299 （

EGFR

wild-type non-drug-resistant cell lines） were cultured

in vitro

. MTT method was used to detect cell activity， and the effect of combined medication was evaluated by the combination index （CI）. The H1975 cells were divided into blank group， low-concentration and high-concentration groups of TPL （5 nmol/L or 15 nmol/L）， gefitinib group （2 μmol/L）， low-concentration and high-concentration groups of TPL+gefitinib （5 nmol/L TPL+2 μmol/L gefitinib， 15 nmol/L TPL+2 μmol/L gefitinib）. Flow cytometry was used to detect the apoptosis of H1975 cells and the distribution of the cell cycle. Molecular docking studies were used to predict the binding ability of TPL to EGFR. The expressions of phosphatidylinositol 3 kinase （PI3K）/protein kinase B （Akt）/mammalian target of rapamycin （mTOR） pathway and autophagy-related proteins [microtubule-associated protein 1 light chain 3α （MAP1LC3A）， MAP1LC3B

]

in H1975 cells were detected by flow cytometry.

RESULTS

TPL had a strong inhibitory effect on the proliferation of H1975 and H1299 cells in a time-dependent and dose-dependent manner. Forty-eight hours treatment of 5 or 15 nmol/L TPL combined with gefitinib had a synergistic inhibitory effect on the proliferation of H1975 cells （CI＜1）， while there was no synergistic inhibitory effect on H1299 cells （CI＞1）. Compared with the blank group， the apoptosis rate and the proportion of H1975 cells at G

phase were increased significantly in administration groups， while the proportions of cells at S phase and G

/M phase （except for several TPL groups） were decreased significantly， and the combination group had better effects （

＜0.05）. Molecular d

ocking studies showed that the hydroxyl radical of TPL could form hydrogen bonds with the Thr854 residue of the product encoded by

EGFR

T790M/L858R mutation. Compared with the blank group， the expressions of pathway-related proteins were down-regulated significantly in administration groups， while those of autophagy-related proteins were up-regulated significantly， and the combination group had better effects （

＜0.05）.

CONCLUSIONS

TPL combined with gefitinib can synergically inhibit the proliferation activity of

EGFR

-mutated NSCLC cells， the mechanism of which may be related to the down-regulation of PI3K/Akt/mTOR pathway and induction of autophagy.

关键词

Keywords

references

LAMB Y N . Osimertinib：a review in previously untreated，EGFR mutation-positive，advanced NSCLC [J ] . Target Oncol ， 2021 ， 16 （ 5 ）： 687 - 695 .

NAGANO T ， TACHIHARA M ， NISHIMURA Y . Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer [J ] . Curr Cancer Drug Targets ， 2019 ， 19 （ 8 ）： 595 - 630 .

DU X J ， YANG B W ， AN Q L ， et al . Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors [J ] . Innovation（Camb）， 2021 ， 2 （ 2 ）： 100103 .

LIU L L ， XIONG X . Clinicopathologic features and molecular biomarkers as predictors of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients [J ] . Curr Oncol ， 2021 ， 29 （ 1 ）： 77 - 93 .

HOU Z Y ， TONG X P ， PENG Y B ， et al . Broad targeting of triptolide to resistance and sensitization for cancer therapy [J ] . Biomedecine Pharmacother ， 2018 ， 104 ： 771 - 780 .

白利平，康向鹏，林立，等 . 自噬介导的雷公藤甲素提高西妥昔单抗对SW480细胞治疗效果的实验研究 [J ] . 中国药理学通报， 2019 ， 35 （ 3 ）： 396 - 402 .

TONG X P ， JIANG P ， LI Y ， et al . Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway [J ] . Chem Pharm Bull（Tokyo）， 2019 ， 67 （ 8 ）： 864 - 871 .

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

PARK C H ， AMARE M ， SAVIN M A ， et al . Prediction of chemotherapy response in human leukemia using an in vitro chemotherapy sensitivity test on the leukemic colony-forming cells [J ] . Blood ， 1980 ， 55 （ 4 ）： 595 - 601 .

刘畅，李振华，阮艳琴，等 . 非小细胞肺癌EGFR-TKIs靶向治疗获得性耐药机制及治疗方案研究进展 [J ] . 临床合理用药杂志， 2022 ， 15 （ 1 ）： 176 - 180 .

刘世光，田伶伶，史冬梅，等 . 吉非替尼联合重组人血管内皮抑制素治疗EGFR突变非小细胞肺癌的临床效果观察 [J ] . 解放军医药杂志， 2022 ， 34 （ 3 ）： 6 - 9 .

GAO J ， ZHANG Y F ， LIU X H ， et al . Triptolide：pharmacological spectrum，biosynthesis，chemical synthesis and derivatives [J ] . Theranostics ， 2021 ， 11 （ 15 ）： 7199 - 7221 .

LIU J ， CHENG H ， HAN L ， et al . Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles [J ] . Drug Des Devel Ther ， 2018 ， 12 ： 3199 - 3209 .

ZHAO G F ， HUANG Z A ， DU X K ， et al . Molecular doc-king studies of traditional Chinese medicinal compounds against known protein targets to treat non-small cell lung carcinomas [J ] . Mol Med Rep ， 2016 ， 14 （ 2 ）： 1132 - 1138 .

XIE C Q ， ZHOU P ， ZUO J ， et al . Triptolide exerts pro-apoptotic and cell cycle arrest activity on drug-resistant human lung cancer A549/Taxol cells via modulation of MAPK and PI3K/Akt signaling pathways [J ] . Oncol Lett ， 2016 ， 12 （ 5 ）： 3586 - 3590 .

ZHU W ， LI Y H ， ZHAO J J ， et al . The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking [J ] . Ann Med ， 2022 ， 54 （ 1 ）： 541 - 552 .

MIAO C C ， HWANG W ， CHU L Y ， et al . LC3A-mediated autophagy regulates lung cancer cell plasticity [J ] . Autophagy ， 2022 ， 18 （ 4 ）： 921 - 934 .

GREMKE N ， POLO P ， DORT A ， et al . mTOR-mediated cancer drug resistance suppresses autophagy and gene-rates a druggable metabolic vulnerability [J ] . Nat Commun ， 2020 ， 11 （ 1 ）： 4684 .

WU J ， ZHAO X G ， SUN Q F ， et al . Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model [J ] . Biomedecine Pharmacother ， 2020 ， 125 ： 109746 .

ZHANG Z R ， ZHANG M X ， LIU H ， et al . AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells [J ] . J Cell Biochem ， 2019 ， 120 （ 1 ）： 756 - 767 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress in the application of microtubulin inhibitors in prostate cancer

Research progress of immune checkpoint inhibitors in the treatment of EGFR-TKIs-resistant NSCLC

Research progress on the role of miRNA in drug resistance of pleural mesothelioma

Research on the role of resveratrol against breast cancer

Regulatory effect of autophagy on the resistance of human liver cancer cell Huh7 to lenvatinib

Related Author

ZHANG Jing

DOU Baokai

GUO Nan

WANG Tongmin

ZHU Yixuan

WANG Yang

WANG Xinmeng

LI Jinsong

Related Institution

Dept. of Pharmacy， Provincial Hospital Affiliated to Shandong First Medical University

College of Pharmacy， Dali University， Yunnan Dali

Dept. of Gastrointestinal and Metabolic Surgery for Weight Loss， the First People’s Hospital of Yunnan Province

School of Basic Medical Sciences， Dali University， Yunnan Dali

Key Laboratory of Clinical Biochemistry of Yunnan Province， Yunnan Dali

⁰

Analysis of the synergistic effect of triptolide combined with gefitinib on EGFR-mutant NSCLC cells

DOI：10.6039/j.issn.1001-0408.2023.18.09

摘要

Abstract

关键词

Keywords

references